← All trials
NCT04976179
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 9, 2021
- Primary completion
- Oct 31, 2022
- Completion date
- Oct 31, 2023
- First posted
- Jul 26, 2021
- Last posted
- Sep 13, 2021
- Enrollment
- 1056
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of LagosLead sponsor
- University of LagosReponsible party - principal investigator
- Aminu Kano Teaching HospitalCollaborator
- University of LagosOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.